564 related articles for article (PubMed ID: 24782109)
1. Successful management of thrombotic thrombocytopenic purpura in a Jehovah's Witness without plasma exchange.
Chai W; Chaudhry A; Rabinowitz AP
J Clin Apher; 2015 Feb; 30(1):46-9. PubMed ID: 24782109
[TBL] [Abstract][Full Text] [Related]
2. Successful management of a Jehovah's Witness with thrombotic thrombocytopenic purpura unwilling to be treated with therapeutic plasma exchange.
Dabak V; Kuriakose P; Raman S
J Clin Apher; 2007; 22(6):330-2. PubMed ID: 18080270
[TBL] [Abstract][Full Text] [Related]
3. Survival of a Jehovah's Witness with thrombotic thrombocytopenic purpura without using plasma: A case report and review of the literature.
Baseri B; Vishwanathan S; Benasher D; Khazan M; Luhrs C; Tsai HM
J Clin Apher; 2019 Oct; 34(5):623-630. PubMed ID: 31116457
[TBL] [Abstract][Full Text] [Related]
4. Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness.
Martin MG; Whitlatch NL; Shah B; Arepally GM
Am J Hematol; 2007 Jul; 82(7):679-81. PubMed ID: 17266059
[TBL] [Abstract][Full Text] [Related]
5. Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient.
Sam C; Desai P; Laber D; Patel A; Visweshwar N; Jaglal M
Transfus Med; 2017 Aug; 27(4):300-302. PubMed ID: 28401611
[TBL] [Abstract][Full Text] [Related]
6. Caplacizumab Without Plasma Exchange for Thrombotic Thrombocytopenic Purpura in a Jehovah's Witness.
Spencer C; Abuhelwa Z; Beran A; Alsughayer A; Sheikh T; Oostra D; Assaly R; Hamouda DM
Am J Ther; 2023 Sep-Oct 01; 30(5):e502-e505. PubMed ID: 37713712
[No Abstract] [Full Text] [Related]
7. To treat or not to treat: a rare case of pseudo-thrombotic thrombocytopenic purpura in a Jehovah's Witness.
Malla M; Seetharam M
Transfusion; 2016 Jan; 56(1):160-3. PubMed ID: 26363181
[TBL] [Abstract][Full Text] [Related]
8. Serial ADAMTS13 measurements during initial plasma exchange therapy guide decisions for management of unresponsive thrombotic thrombocytopenic purpura.
van der Veen BS; Besseling R; Hoogendoorn M
Transfusion; 2015 Oct; 55(10):2511-5. PubMed ID: 26308736
[TBL] [Abstract][Full Text] [Related]
9. A case series of atypical presentations of thrombotic thrombocytopenic purpura.
Imanirad I; Rajasekhar A; Zumberg M
J Clin Apher; 2012; 27(4):221-6. PubMed ID: 22467376
[TBL] [Abstract][Full Text] [Related]
10. [Successful treatment with rituximab in a patient with refractory thrombotic thrombocytopenic purpura refractory to plasma exchange].
Koshino M; Kudou D; Okoshi Y; Obara N; Simizu S; Mukai HY; Suzukawa K; Hasegawa Y; Kojima H; Nagasawa T; Chiba S
Rinsho Ketsueki; 2010 Feb; 51(2):127-31. PubMed ID: 20379104
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic modalities in thrombotic thrombocytopenic purpura management among Jehovah's Witness patients: A review of reported cases.
Tran MH
Transfus Apher Sci; 2023 Aug; 62(4):103706. PubMed ID: 36990894
[TBL] [Abstract][Full Text] [Related]
12. [Successful delivery following treatment with plasma exchange in a female patient with thrombotic thrombocytopenic purpura].
Takagi Y; Adachi Y; Tsujimura A; Tsushita K
Rinsho Ketsueki; 2012 Aug; 53(8):770-3. PubMed ID: 22975818
[TBL] [Abstract][Full Text] [Related]
13. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.
Pandey S; Nakagawa M; Rosenbaum ER; Arnaoutakis K; Hutchins LF; Makhoul I; Milojkovic N; Cottler-Fox M
J Clin Apher; 2015 Feb; 30(1):50-4. PubMed ID: 25042026
[TBL] [Abstract][Full Text] [Related]
14. [Multi-facetted clinical presentation of thrombotic thrombocytopenic purpura].
Niemann CU; Jurlander J; Daugaard G; Friis-Hansen L
Ugeskr Laeger; 2009 Jan; 171(5):340-2. PubMed ID: 19176177
[TBL] [Abstract][Full Text] [Related]
15. Successful Management of Thrombotic Thrombocytopenic Purpura in a Jehovah's Witness: An Individualized Approach With Joint Decision-Making.
Lim MY; Greenberg CS
J Patient Exp; 2020 Feb; 7(1):8-11. PubMed ID: 32128364
[TBL] [Abstract][Full Text] [Related]
16. COVID 19 infection associated with thrombotic thrombocytopenic purpura.
Dhingra G; Maji M; Mandal S; Vaniyath S; Negi G; Nath UK
J Thromb Thrombolysis; 2021 Aug; 52(2):504-507. PubMed ID: 33904053
[TBL] [Abstract][Full Text] [Related]
17. [Refractory thrombotic thrombocytopenic purpura successfully treated with a combination of rituximab and vincristine].
Kaneko H; Matsumoto M; Okamoto K; Chyonabayashi K; Hishizawa M; Watanabe M; Fujimura Y; Tsudo M
Rinsho Ketsueki; 2007 Feb; 48(2):144-7. PubMed ID: 17370643
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin as an adjunct to plasma exchange for the treatment of chronic thrombotic thrombocytopenic purpura.
Moore JC; Arnold DM; Leber BF; Clare R; Molnar GJ; Kelton JG
Vox Sang; 2007 Aug; 93(2):173-5. PubMed ID: 17683362
[TBL] [Abstract][Full Text] [Related]
19. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
Shah N; Rutherford C; Matevosyan K; Shen YM; Sarode R
Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495
[TBL] [Abstract][Full Text] [Related]
20. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
Coppo P; Veyradier A
Presse Med; 2012 Mar; 41(3 Pt 2):e163-76. PubMed ID: 22265954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
